NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

IM Cannabis Corp. (IMCC) Stock Analysis

IM Cannabis Corp. (IMCC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMCC

$1.19

−$0.21 (−15.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMCC with… →

IMCC Key Statistics

As of Oct 21, 2026
Trading
Open
$1.37
Previous Close
$1.40
Day's Range
1.13–1.40
52-Week Range
1.13–77.10
Volume
128.98K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.21
Valuation
Market Cap
$1.96M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.04
EPS (ttm)Profit attributable to each share over the last twelve months.
−71.41
Financials (FY)
Revenue (FY)
$54.73M+1.30%
Net Income (FY)
−$11.32M
Profit marginThe share of revenue left as profit after all costs and taxes.
−39.13%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.65M
1-Year Return
−97.98%
Dividend and dates
Avg Volume
2.76M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMCC closed at $1.19, −97.98% over 1 year.

IM Cannabis Corp. (IMCC) has a market capitalization of $1.96M.

In fiscal 2025, IMCC reported revenue of $54.73M.

IMCC Stock Return by Calendar Year

IM Cannabis Corp. (IMCC) return since May 2020: what $10,000 became

1 year
$10,000 $202
−97.98%
5 years
$10,000 $2
−99.98%
Since May 2020
$10,000 $3
−99.97%

If you had invested $10,000 in IM Cannabis Corp. (IMCC) at the close on May 20, 2020, the earliest close on record here, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −71.25% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−97.15%
2025−40.37%
2024+8.82%
2023−63.38%
2022−97.08%
2021−57.18%
2020 (partial year)+294.74%

As of October 21, 2026.

IMCC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$54.73M−$11.32M−20.7%
2024$54.03M−$10.59M−19.6%
2023$48.80M−$9.50M−19.5%
2022$54.34M−$188.89M−347.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$54.73M$9.69M−$11.59M−$11.32M−20.7%
2024$54.03M$8.45M−$10.23M−$10.59M−19.6%
2023$48.80M$9.85M−$12.18M−$9.50M−19.5%
2022$54.34M$9.16M−$22.50M−$188.89M−347.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMCC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricIMCCDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.042.100.0x the median
Profit margin−39.13%−8.14%31.0 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

IM Cannabis Corp. (IMCC) is capitalised at $1.96M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 44 employees.

The most recent close on file for IMCC is $1.19, dated October 21, 2026. That is −$0.21 (−15.00%) against the previous close. The 52-week range on file runs from $1.13 to $77.10. The latest close sits 5.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $54.73M. Against the prior fiscal year total of $54.03M, that is a change of +1.30%. The same year closed with a net loss of $11.32M. The reported profit margin is −39.13%. That is 31 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −71.41.

Across the 4 fiscal years on file, revenue moves from $54.34M in 2022 to $54.73M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.04. On price-to-sales that is 0 times the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.21. Annualized volatility over the trailing 6 years is 135.68%. Over the trailing twelve months the total return is −97.98%. Measured over 5 years, that is −81.77% a year compounded.

Growth & Income

No dividend is on file for IMCC.

The strongest complete calendar year on file is 2024 at +8.82%; the weakest is 2022 at −97.08%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −97.15%.

Peer Comparison

IM Cannabis Corp. (IMCC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IM Cannabis Corp. IMCC $1.96M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. IM Cannabis Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About IM Cannabis Corp.

IM Cannabis Corp. engages in importation, distribution and sale of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and full-spectrum cannabis extracts under the IMC, BLKMT, and LOT420 brands. The company serves medical patients. IM Cannabis Corp. was founded in 2008 and is headquartered in Vancouver, Canada.

Visit website →